



## ASX ANNOUNCEMENT

18 December 2023

### CLEANSING NOTICE

**Melbourne, Australia – Opyl Limited (ASX:OPL)** provides this notice under section 708A of the Corporations Act 2001 (Cth) (Corporations Act) and states the following:

- a) the Company has issued fully paid ordinary shares (Securities) in number, at the issue price, on the terms and for the purposes as set out in the ASX Appendix 2A lodged on 18 December 2023.
- b) the Securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) section 674 of the Corporations Act as it applies to the Company; and
- e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

The Board has authorised this announcement for release to the ASX.

**- ENDS -**

#### For investor enquiries:

Stefan Jacobs  
Vesparum Capital  
Phone: +61 3 8582 4800  
Email: [opyl@vesparum.com](mailto:opyl@vesparum.com)

#### For general enquiries:

Email: [info@opyl.ai](mailto:info@opyl.ai)  
Website: [www.opyl.ai](http://www.opyl.ai)

#### About Opyl Limited

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials and predicting outcomes. Our platforms provide targeted insights that make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money. Our key offering for biopharma, medtech, government and healthcare organisations are Opin.ai (clinical trial recruitment solutions) and Trial Key (clinical trial predictive analytics and protocol design).